CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,846 enrolled
Drug / intervention
undefineddrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Phase III clinical trials that included overall survival (OS) as endpoint and another time-to-event endpoint as primary or secondary endpoint
  • ✓Phase III clinical trials that included patients with metastatic soft tissue sarcoma
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02873923
NCT02873923N/ACompleted
CompareCT.gov

Survival Endpoints in Randomized Clinical Trials in Sarcoma Patients: Meta-analyses for the Assessment of the Impact Various Definitions on Trials' Results and of Surrogate Properties for OS

Institut Bergonié·observational·Posted Aug 22, 2016·Updated Jan 25, 2021

In Brief

An observational study evaluating undefined for Cancer. Completed, enrolled 2,846 participants.

Detailed Summary

The DATECAN-2 project aims at assessing the surrogate properties for OS of several time-to-event endpoints through meta-analyses of completed and published randomized controlled trials. Two main cancer localization are concerned: breast cancer and soft-tissue sarcomas. The impact of survival endpoints' definitions on the trials' results and conclusions will also be evaluated.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
Countries--
CollaboratorsNational Cancer Institute, France, Ligue contre le cancer, France, Institut du Cancer de Montpellier - Val d'Aurelle, Centre Georges Francois Leclerc

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 22, 2016
Enrollment StartOct 1, 2012
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago

Interventions

undefineddrug

Chemotherapy drug (meta-analyses of randomized trials)